Technical Analysis for BBIO - BridgeBio Pharma, Inc.

Grade Last Price % Change Price Change
grade F 28.38 1.90% 0.53
BBIO closed up 1.9 percent on Friday, August 7, 2020, on 32 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Aug 17
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical BBIO trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Death Cross Bearish 1.90%
Stochastic Buy Signal Bullish 1.90%
Lower Bollinger Band Walk Weakness 1.90%
Up 3 Days in a Row Strength 1.90%
Oversold Stochastic Weakness 1.90%
Slingshot Bearish Bearish Swing Setup 2.45%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Organ Systems Anatomy Tyrosine Kinase Receptors Protein Kinase Inhibitor Cardiomyopathy Tyrosine Kinase Familial Amyloid Polyneuropathy Achondroplasia Congenital Adrenal Hyperplasia Fibroblast Growth Factor Receptor Hyperplasia Transthyretin TTR Amyloidosis

Is BBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 48.36
52 Week Low 14.23
Average Volume 722,768
200-Day Moving Average 30.61
50-Day Moving Average 30.34
20-Day Moving Average 29.67
10-Day Moving Average 28.91
Average True Range 1.78
ADX 18.74
+DI 16.25
-DI 25.45
Chandelier Exit (Long, 3 ATRs ) 27.53
Chandelier Exit (Short, 3 ATRs ) 31.50
Upper Bollinger Band 32.78
Lower Bollinger Band 26.56
Percent B (%b) 0.29
BandWidth 20.96
MACD Line -0.86
MACD Signal Line -0.62
MACD Histogram -0.2426
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.74
Resistance 3 (R3) 29.72 29.25 29.51
Resistance 2 (R2) 29.25 28.91 29.26 29.44
Resistance 1 (R1) 28.82 28.69 29.04 28.83 29.36
Pivot Point 28.35 28.35 28.46 28.36 28.35
Support 1 (S1) 27.91 28.00 28.13 27.93 27.40
Support 2 (S2) 27.44 27.79 27.45 27.32
Support 3 (S3) 27.01 27.44 27.25
Support 4 (S4) 27.02